# Fresenius Medical Care Ventures (FMS) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/FMS
## Company Profile
- Ticker: FMS
- Exchange: NASDAQ
- Sector: Biotechnology
- Location: United States
- Tags: Biopharma, Pharmaceuticals, MedTech, Life Science Tools
## Stock Data
- Close: 24.11 USD
- Market cap: 12901844825.199999 USD
- Last updated: 2026-07-17
## Business Overview
Fresenius Medical Care Ventures is a medical devices company focused on product adoption, procedure volume, and how clinical workflow converts into recurring demand.
## Why The Stock Is Moving

FMS is trading with a steady catalyst profile while investors wait for the next headline that changes the story.

## Geographic Base

Headquartered in the United States and listed on NYSE, Fresenius Medical Care Ventures is followed within the medical devices universe for its exposure to procedure trends and reimbursement support.

## Business Model

Fresenius Medical Care Ventures makes its case through product adoption, operating discipline, and the pace at which the installed base turns into recurring revenue.

## Landscape Position

Compared with drug-development peers, Fresenius Medical Care Ventures trades more like a product-adoption story, where reimbursement, procedure volume, and refresh cycles matter more than a single clinical binary.

## Recent News
- 2026-07-20 10:59 EST — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company
- 2026-07-20 07:00 EST — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc
- 2026-07-17 09:00 EST — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc
- 2026-07-16 12:31 EST — [Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia](https://biopharmsignal.com/news/MRK/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-1b899588) — Source: Merck
- 2026-07-16 12:00 EST — [Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-conference-call-discussing-second-quarter-2026-financial-resu-458d7635) — Source: Alnylam Pharmaceuticals, Inc.